Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• Globocan. Country Fast Stats2008 Available from: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=968Accessed September 12, 2012
   Google Scholar
• BeckerNEpidemiology of multiple myelomaRecent Results Cancer Res2011183253521509679
   PubMedGoogle Scholar
• AlegreAVicunaIAguadoBSafety and efficacy of lenalidomide in relapsed or refractory multiple myelomaClin Med Insights Oncol2012611022253550
   PubMedGoogle Scholar
• LudwigHBolejackVCrowleyJSurvival and years of life lost in different age cohorts of patients with multiple myelomaJ Clin Oncol2010281599160520177027
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood20081112516252017975015
   PubMed Web of Science ®Google Scholar
• BrennerHGondosAPulteDRecent major improvement in long-term survival of younger patients with multiple myelomaBlood20081112521252617901246
   PubMed Web of Science ®Google Scholar
• BrennerHGondosAPulteDExpected long-term survival of patients diagnosed with multiple myeloma in 2006–2010Haematologica20099427027519144659
   PubMed Web of Science ®Google Scholar
• KastritisEZervasKSymeonidisAImproved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)Leukemia2009231152115719225533
   PubMed Web of Science ®Google Scholar
• GreenbergAJVachonCMRajkumarSVDisparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whitesLeukemia20122660961422193966
   PubMed Web of Science ®Google Scholar
• KvamAKFayersPHjermstadMGulbrandsenNWisloffFHealth-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendationsEur J Haematol20098327928919558508
   PubMed Web of Science ®Google Scholar
• GulbrandsenNHjermstadMJWisloffFInterpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differencesEur J Haematol20047217218014962235
   PubMed Web of Science ®Google Scholar
• DurieBGNew approaches to treatment for multiple myeloma: durable remission and quality of life as primary goalsClin Lymphoma Myeloma2005618119016354323
   PubMedGoogle Scholar
• EngelhardtMKleberMUdiJConsensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesLeuk Lymphoma2010511424144320509769
   PubMed Web of Science ®Google Scholar
• CookREconomic and clinical impact of multiple myeloma to managed careJ Manag Care Pharm200814Suppl 7192518774882
   PubMed Web of Science ®Google Scholar
• MollerJNicklassonLMurthyACost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone versus bortezomibJ Med Econ20111469069721892856
   PubMedGoogle Scholar
• CaroJJPharmacoeconomic analyses using discrete event simulationPharmacoeconomics20052332333215853433
   PubMed Web of Science ®Google Scholar
• WeberDMChenCNiesvizkyRLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med20073572133214218032763
   PubMed Web of Science ®Google Scholar
• DimopoulosMSpencerAAttalMLenalidomide plus dexamethasone for relapsed or refractory multiple myelomaN Engl J Med20073572123213218032762
   PubMed Web of Science ®Google Scholar
• DimopoulosMAChenCSpencerALong-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia2009232147215219626046
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or highdose dexamethasone for relapsed multiple myelomaN Engl J Med20053522487249815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMExtended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood20071103557356017690257
   PubMed Web of Science ®Google Scholar
• BladeJSamsonDReeceDCriteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow TransplantBr J Haematol1998102111511239753033
   PubMed Web of Science ®Google Scholar
• ManiadakisNDafniUFragoulakisVEconomic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trialAnn Oncol20092027828518842612
   PubMed Web of Science ®Google Scholar
• ManiadakisNFragoulakisVPallisAPrezerakosPGeorgouliasVEconomic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in GreeceLung Cancer20075827528117688969
   PubMed Web of Science ®Google Scholar
• Available from: http://www.yyka.govAccessed September 15, 2012
   Google Scholar
• ManiadakisNFragoulakisVPectasidesDFountzilasGXELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysisCurr Med Res Opin20092579780519215190
   PubMed Web of Science ®Google Scholar
• van AgthovenMSegerenCMBuijtIA cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III studyEur J Cancer2004401159116915110879
   PubMed Web of Science ®Google Scholar
• DesgagneACastillouxAMAngersJFLeLorierJThe use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed dataPharmacoeconomics1998135 Pt 148749710180748
   PubMed Web of Science ®Google Scholar
• McCabeCClaxtonKCulyerAJThe NICE cost-effectiveness threshold: what it is and what that meansPharmacoeconomics20082673374418767894
   PubMed Web of Science ®Google Scholar
• SimoensSBiosimilar medicines and cost-effectivenessClinicoecon Outcomes Res20113293621935330
   PubMedGoogle Scholar
• ZhaoFLYueMYangHWangTWuJHLiSCWillingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitisMed Care20114926727221224742
   PubMed Web of Science ®Google Scholar
• Hellenic Statistical Authority Available from: http://www.statistics.grAccessed September 15, 2012
   Google Scholar
• FragoulakisVKourlabaGGoumenosDKonstantoulakisMManiadakisNEconomic evaluation of intravenous iron treatments in the management of anemia patients in GreeceClinicoecon Outcomes Res2012412713422629113
   PubMedGoogle Scholar
• MessoriAMarateaDNozzoliCBosiAThe role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic informationPharmacoeconomics20112926928521395348
   PubMed Web of Science ®Google Scholar
• BrownRESternSDhanasiriSScheySLenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and WalesEur J Health Econ5102012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• FélixJAlmeidaJVandewalleBA comprehensive cost-effectiveness analysis of lenalidomide for multiple myeloma patients who have received at least one prior therapyValue Health201215A218
   Web of Science ®Google Scholar
• DrummondMBarbieriMCookJTransferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force reportValue Health20091240941819900249
   PubMed Web of Science ®Google Scholar
• PicotJCooperKBryantJCleggAJThe clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluationHealth Technol Assess2011151204
   Web of Science ®Google Scholar
• GaultneyJGRedekopWKSonneveldPUyl-de GrootCANovel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic valueExpert Rev Anticancer Ther20121283985422716498
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol20111243144021507715
   PubMed Web of Science ®Google Scholar
• DimopoulosMAKastritisEChristoulasDTreatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapiesLeukemia2010241769177820739955
   PubMed Web of Science ®Google Scholar
• DimopoulosMARoussouMGkotzamanidouMThe role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myelomaLeukemia20132742342922763386
   PubMed Web of Science ®Google Scholar
• KapoorPFonsecaRRajkumarSVEvidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapieMayo Clin Proc20108553253720511484
   PubMed Web of Science ®Google Scholar
• ReeceDSongKWFuTInfluence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13Blood200911452252519332768
   PubMed Web of Science ®Google Scholar